Purpose of review Antiphospholipid syndrome (APS) is defined as the association of thrombotic events and/or obstetric morbidity in patients persistently positive for antiphospholipid antibodies (aPL). In this review, we will highlight the most important clinical presentations of APS with a focus on the obstetric morbidity, the current management strategies and the outlook for the future.
INTRODUCTION
Antiphospholipid syndrome (APS) is classified as the association of arterial and/or venous thromboses and/ or obstetric morbidity in patients who test positive for antiphospholipid antibodies (aPL) on two occasions at least 12 weeks apart. Antibodies currently included in the APS classification criteria are lupus anticoagulant (LAC), IgG and/or IgM anticardiolipin (aCL) and/or IgG and/or IgM antib2glycoprotein1 antibodies (antib2GP1) [1] . The classification criteria for APS, which often also guide diagnosis, were originally outlined in the Sapporo criteria and were updated in 2006 and are now referred to as the Sydney criteria [1, 2] .
Initially, the association of circulating LAC and aCL antibodies, thrombosis, pregnancy loss and thrombocytopenia was described in women suffering from systemic lupus erythematosus (SLE) [3] . This has resulted in that APS in patients with SLE has been referred to as 'secondary', but it is now widely accepted that APS is an autoimmune entity of its own, and that it may well exist in the absence of SLE [4] . APS is one of the main acquired prothrombotic conditions that predisposes to venous thromboembolism (also referred to as 'thrombophilia'). APS is unique in that thrombotic events can happen in the venous and the arterial system, including the microvascular system.
The other hallmark of this syndrome is pregnancy morbidity, which includes recurrent first trimester pregnancy loss, intrauterine growth restriction (IUGR), preeclampsia (PET), premature birth and intrauterine death (IUD) [1, 5] . Data from a retrospective cohort of 500 women with a history of recurrent first trimester pregnancy loss suggested that 26.4% are associated with the presence of aPL [6] . aPL-related PET, premature birth or fetal loss are seen in 10-20% of APS pregnancies [7] . In view of these pregnancy complications, APS has been referred to as the most frequent acquired risk factor for a treatable cause of recurrent pregnancy loss [8] .
The current standard of treatment of APS is mainly relying on antithrombotic and antiaggregation treatment [9] . The combination of low-dose aspirin (LDA) and heparin [unfractionated heparin or low molecular weight heparin (LMWH)] has resulted in a live birth rate of 70-80% [10] .
Recent data suggest a role for drugs including hydroxychloroquine (HCQ) [11 && ,12] and pravastatin [13 && ], but their efficacy and safety in the setting of aPL pregnancies requires confirmation in prospective randomized controlled trials [14] .
The potential beneficial role of pravastatin was highlighted in a retrospective case control study on patients with manifest aPL-related PET and/or IUGR on standard treatment with LDA and LMWH [13 && ]. Moreover, the immunmodulator HCQ is currently the centre for attention not only in thrombotic, but also in obstetric APS. Retrospective data suggest that HCQ reduces the risk of thrombosis in APS [15] and also improves pregnancy outcomes in women with aPL-related pregnancy complications [12, 16] . Upcoming randomized controlled trials will hopefully provide the answer in the near future [17] .
ANTIPHOSPHOLIPID ANTIBODIES
aPLs are a heterogeneous group of antibodies and can be detected in three different ways. The available and required assays detect LAC, aCL antibodies and ab2GPI and patients may be positive for one, two or three of these tests [1] . The type of aPL, the titre level and the presence of multiple antibodies have been associated with different risk profiles. LAC for example has been described as the best predictor for pregnancy loss and thrombosis [18] . Some authors suggest that the aPL titre is of clinical interest [19] , especially in aPL-related pregnancy complications where low-to-medium titre antibodies have been suggested to be of clinical relevance [19] . Regarding the individual-specific immunoglobulin isotypes, a positive aCL IgG has been associated to a higher risk of adverse pregnancy outcomes compared to IgM, and IgA seems not to be an independent predictor [20] . Galli et al. [18] published a systematic review including 63 studies and concluded that LAC (and aCL IgG) is the strongest risk factor for thrombosis. The presence of all three antibodies (referred to as 'triple positive' patients) seems to be associated with a high risk for thrombotic APS [21] .
Conversely, there is increasing evidence that patients with low aPL titres can experience poor pregnancy outcomes similarly to high-titre patients [19, 22, 23] . These observations suggest that in contrast to thrombotic events, low-titer aPLs can play a significant role in Obstetric APS (OAPS) and that the actual classification criteria do not include all the OAPS cases.
More specific details on aPL included in the current classification criteria are beyond the scope of this review and can be read in detail elsewhere [24] .
PATHOGENESIS

Thrombosis and fetal loss
aPLs have the unique ability to induce thrombus formation in the arterial and/or venous vasculature and/or the microcirculation [25] [26] [27] . The exact mechanism by which aPLs cause prothrombotic changes has been debated, but remains as yet fully explained. aPLs have the potential to activate several cell types involved in haemostasis including endothelial cells, monocytes and platelets [28] . Other experiments have shown that some aPLs are able to inhibit fibrinolysis and the protein C pathway [29] . It is therefore not surprising that placental thrombosis impairing the maternal-fetal blood exchange has been suggested to play a major role in obstetric APS. Moreover, it has been reported that aPLs are able to disrupt the anticoagulant annexin A5 shield on trophoblast and endothelial cell monolayers, resulting in fetal loss [30, 31] .
KEY POINTS
Antiphospholipid syndrome is defined as the association of thrombotic events and/or obstetric morbidity in patients persistently positive for antiphospholipid antibodies.
Antiphospholipid syndrome is among the most frequent acquired risk factors for a treatable cause of recurrent pregnancy loss.
Current treatment of obstetric APS is mainly based on aspirin and heparin, and new options are being explored.
Ultimately, it maybe that multiple mechanisms are responsible for aPL causing thrombosis in one individual.
Placental infarctions were initially thought to be the main cause of fetal loss. However, they were not the universal histopathological findings in human placental samples and other mechanisms have therefore been proposed to underlie the pathophysiology of obstetric APS [32] . De Wolf et al. [33] for example showed in placental tissue of LAC positive patients evidence of thrombosis alongside acute and chronic inflammation. These findings were in line with a study by Stone et al. [34] who found increased infiltration of inflammatory cells, particularly macrophages in placentae of women with aPL.
Moreover, it is very likely that the pathogenesis of aPL-related recurrent preembryonic loss differs from the pathogenesis of morbidity occurring in late pregnancy [35] . aPLs have direct pathogenic effects on placentation and apoptosis of trophoblast cells, which may play an important role, particularly recurrent first trimester losses [36] . This association is supported by murine models, which suggest that the complement system is the key mediator of aPLrelated pregnancy loss and fetal growth restriction (FGR). In a pregnant murine model based on BALB/c mice and FcRy mice, mice infused with aPL had increased fetal losses and exhibited FGR. Mice with complement deficiency or complement blockage showed protection against aPL-induced pregnancy complications, as did treatment with heparins (which have an anticomplement effect) as opposed to fondaparinux with no anticomplement effect [37, 38] . Increased complement deposition products were observed in the decidua of pregnant mice infused with aPL, whereas mice depleted of neutrophils or mice treated with heparin did not show pregnancy loss or growth restriction and there was a lack of complement deposition in their decidual tissue [37] . The findings from these animal studies were supported by human studies by Shamonki et al. [39] who showed that placentae of women with aPL have increased complement deposition. Thus, it is now widely accepted that both thrombosis and inflammation seem to mediate aPL-related ischaemic placental pregnancy complications in women with aPL [24] .
CLINCAL MANIFESTATIONS OF THE ANTIPHOSPHOLIPID SYNDROME
Thrombotic antiphospholipid syndrome
As mentioned above, aPL-related thrombosis can occur in any vascular bed [1] . The most frequent arterial manifestations are neurological manifestations such as stroke or transient ischaemic attacks, whereas the most common venous thromboembolic manifestations include deep vein thrombosis and pulmonary embolism [7] .
Other manifestations including retinal artery or vein thrombosis, amaurosis fugax, renal thrombotic microangiopahty, pulmonary hypertension and vascular dementia are seen less frequent in 10% of patients, whereas adrenal haemorrhage, avascular necrosis, pathological bone fractures due to bony infarcts or Budd-Chiari syndrome are seen in 1% of APS patients [7] . Livedo reticularis, the most common skin manifestation, is sometimes associated with occlusive arterial events in the brain and referred to as Sneddon's syndrome [7, 40] . The most life-threatening clinical manifestation is rare and referred to as catastrophic APS (CAPS). CAPS is classified by thrombosis in at least three organs often accompanied by small vessel thrombosis developing over a short period and is associated with a mortality of over 50% [41, 42] .
Nonthrombotic APS manifestations can include thrombocytopenia, which is usually associated with a risk of thrombosis rather than bleeding complications; cardiac valve abnormalities -minor thickening and/or incompetence due to valve thrombosis. The valves rarely cause haemodynamic consequences.
Obstetric antiphospholipid syndrome
Recurrent early miscarriages
The obstetric manifestations include recurrent first trimester pregnancy loss and conditions associated with ischaemic placental dysfunction such as IUD, stillbirth, PET, premature birth and FGR affecting up to 10-20% of APS pregnancies [1, 7] . Unfortunately, the definition of miscarriage varies which makes the comparison of reported studies challenging. In Europe, the most widely used definition for early miscarriage is pregnancy loss within the first 12 completed weeks of pregnancy. Ten to 15% of all clinically recognized pregnancies end in this way [43] . The most common reasons for early miscarriage and recurrent miscarriages are genetic abnormalities, cervical weakness, anatomic variations, endocrine factors and immune factors, such as thyroid factors, infective agents, that is TORCH (Toxoplasmosis, Other, Rubella, Cytomegalovirus, Herpes simplex virus) and aPL [44] . In a cohort of 500 women with a history of recurrent miscarriages, Rai et al. [6] found 9.6% of women to be persistently positive for lupus anticoagulant, whereas aCL IgG and IgM were found in 3.3% and 2.2%, respectively. The prevention of recurrent early miscarriages is the only area in obstetric APS, in which treatment is based on several clinical trials, including randomized controlled trials. This will be discussed in more depth under management.
Late pregnancy loss
Late pregnancy loss or fetal death is defined as pregnancy loss after 10 weeks of gestation, whereas stillbirth indicates a loss after 20 weeks by some although the definition recommended by WHO for international comparison is a baby born with no signs of life at or after 28 weeks' gestation. The only population-based study (the stillbirth collaborative research network) reported the association of aPL (aCL and antib2GPI) with a significant increased odds of stillbirth (3-5 fold) in 582 cases of fetal death beyond 20 weeks of gestation. However, the group did not measure LAC, and aCls were not reassessed after 12 weeks interval to confirm persistency of the aPL [45] .
Placental insufficiency and preeclampsia PET and/or placental insufficiency can manifest as FGR and occurs in about 2-8% of mainly first pregnancies, whereas severe PET is found in 0.5% of pregnancies in developed countries. Most prospective observational studies support the association of aPL with PET and placental insufficiency. A recent systematic meta-analysis showed that moderate-tohigh level aCLs are associated with PET [46] . Moreover, several prospective and retrospective studies have shown that the persistent presence of hightitre aPL is associated with FGR and preterm deliveries [7, 47, 48] . Data from case-control studies have shown that among patients with a history of PET or FGR, aPLs were found in up to 50%, compared to 7% or less in healthy pregnant women [47] . There is to date only one randomized controlled trial assessing the management and prevention of PET and FGR in women with aPL. The aim of the multicentre study (FRUIT-RCT) was to examine if combined treatment with LMWH and aspirin reduces recurrent hypertensive disorders of pregnancy (hypertensive disorder: preeclampsia, eclampsia or HELLP syndrome) in women with aPL with a previous delivery for HD and/or small-for-gestational-age birth weight before 34 weeks gestation [49] . Unfortunately, the study was terminated because of very low event rates and the final analysis on 33 (recruitment target was 85 women to detect a 50% risk reduction) women did not show any significant difference between aspirin alone or aspirin in combination with LMWH [49] .
A recent meta-analysis comparing LMWH versus no LMWH for the prevention of recurrent placentamediated pregnancy complications in 848 pregnant women with a previous history placental-mediated pregnancy complications showed a relative risk reduction of 0.52 [95% confidence interval (CI), 0.32-0.86] in women treated with LMWH [50] . The meta-analysis did not confirm any reduction of early pregnancy loss (<20 weeks) in patients with prior placenta-mediated pregnancy complications, whereas a statistically nonsignificant reduction in late pregnancy loss (>20 weeks) was observed [50] .
Very recently, results from a multicentre randomized controlled trial on 150 mg aspirin once daily versus placebo conducted in 1776 pregnant women at high risk for preterm preeclampsia have shown to reduce the risk of preterm preeclampsia before week 34 of gestation significantly [1.6 versus 4.3%, odds ratio (OR) 0.38, 95th CI 0.20-0.74; P ¼ 0.004] [51] .
MANAGEMENT OF ANTIPHOSPHOLIPID SYNDROME
Thrombotic antiphospholipid syndrome
The current mainstay of treatment in the thrombotic manifestations of APS is based on anticoagulation, including vitamin K antagonist (VKA) or heparin and antiplatelet therapy, such as LDA. Preliminary data supporting the use of direct oral anticoagulant (DOAC) in APS patients with previous venous thromboembolism are available, and other trials are also ongoing, as yet the evidence base is incomplete to fully support the use of DOACs in APS. Very rarely immune-modulating agents, immunosupression and anticomplement therapy, are used in patients who do not respond to antithrombotic medication or in particularly severe conditions such as CAPS.
Obstetric antiphospholipid syndrome
Pregnancy in APS is regarded as high-risk pregnancies and the main aim of surveillance and treatment in pregnant women with aPL is to optimize maternal and fetal pregnancy outcomes. More specifically, the objective of antenatal care in pregnant patients with APS is close observation for maternal thrombosis, APS nephropathy, hypertension, proteinuria and other features of preeclampsia and to monitor fetal growth.
Current standard of care for patients with obstetric APS includes treatment with low LDA (75-100 mg/day) and low molecular heparin (e.g. subcutaneous enoxaparin, dalteparin, nadroparin or subcutaneous tinzaparin) or unfractionated heparin. These recommendations are based on results from three randomized controlled trials comparing LDA alone or in combination therapy with heparin in women with APS [52] [53] [54] . Rai et al. [52] showed a significantly higher rate of live births with LDA and unfractionated heparin (5000 units BD) versus LDA alone (71 versus 42%; OR, 3.37; 95% CI, 1.40-8.10). Similarly, Kutteh [54] . reported a significant improvement in the live birth rate with LDA and heparin versus LDA alone (80 versus 44%; P < 0.05).However, no differences in outcome with combination therapy versus LDA were found in two other randomized trials, both using LMWH, with live birth rates approaching 80% in both arms. The heterogeneity in the conclusions seems attributable to the relatively poor outcomes in women receiving LDA only in the two former studies [53, 55] . Moreover, data from observational studies have reported 79-100% pregnancy success rates with LDA alone in this subgroup of women [56] . The current recommendation for the treatment of obstetric APS is to start with LDA and to escalate to additional LMWH if LDA alone is associated with pregnancy loss. Data to support this management have recently been published [10] .
PREGNANCY COUNSELLING AND SURVEILLANCE
Overall, there is agreement that pregnant women with obstetric APS require close education and monitoring of maternal and fetal health by a multidisciplinary team consisting of obstetricians, rheumatologists and haematologists with special interest in APS [57, 58] . All women should be assessed regarding risk factors for venous thromboembolism and should receive thromboprophylaxis postpartum if indicated according to local guidelines. The Royal College of Gynaecology in the United Kingdom for example recommends for aPL-positive women without clinical manifestations of APS 7 days post partum thromboprphylaxis and for women with APS, this is extended to 6 weeks [59] .
All women with APS can potentially give natural birth, unless there are obstetric reasons that suggest otherwise. Moreover, all women should be encouraged to stop smoking and to reduce/cease their alcohol intake according to the National Pregnancy Guidelines. Patients with a recent thrombotic event in the last 3 months, particularly arterial, and/or uncontrolled hypertension, should be encouraged to postpone further pregnancies [8, 24] . Patients with pulmonary hypertension in general are advised against pregnancy [8, 60] .
Women with previous thrombosis should receive long-term anticoagulation once the risk of postpartum haemorrhage has settled. Both VKA and heparins are compatible with breastfeeding [61, 62] . With regard to fetal monitoring during pregnancy, bilateral uterine notching between 23 and 25 weeks' gestation has been shown to be an independent risk factor for the development of early-onset preeclampsia and gestational hypertension. Thus, bilateral uterine artery notching should be considered in the assessment of risk for the development of these pregnancy complications [63, 64] .
Thrombotic risk assessment should also be considered in patients with a history of obstetric APS. Among other, Lefevre et al. [65] showed that patients with obstetric APS have a higher thrombotic risk when compared to healthy women (3.3 versus 0-0.5/100 patient-years), even if treated with LDA.
Similarly, in a 10-year observational study of 1592 women with pure obstetric APS and no history of thrombosis, Gris et al. [66] showed that lupus anticoagulant was a risk factor for unprovoked proximal and distal deep and superficial vein thrombosis and similar results have been proved in other studies [67] .
TREATMENT PERSPECTIVES IN OBSTETRIC ANTIPHOSPHOLIPID SYNDROME
The current treatment regimens to prevent obstetric morbidity in APS have improved pregnancy outcome to a live birth rate of over 70% as mentioned above [68] . As 30% of women continue to have pregnancy complications, international groups are currently assessing different options in order to improve pregnancy outcomes in women with APS. The additional use of low-dose steroids has been assessed in refractory APS [69] . Intravenous immunoglobulin has been suggested to improve pregnancy complications in obstetric APS, with no significant improvement in pregnancy outcomes [70] .
Interesting data on pravastatin suggest a beneficial role in those women with established aPLrelated PET. In their case series, 11 patients treated with 20 mg pravastatin in addition to standard treatment, whereas the controls continued LDA and LWMH only. In all patients exposed to pravastatin, signs of preeclampsia, such as blood pressure and proteinuria improved and signs of placental perfusion remained stable without further deterioration compared to the control group [13 && ]. The role of HCQ has also been assessed. The immunmoldulator HCQ may have beneficial effects not only in the management of thrombotic APS [71] , but also in the prevention of pregnancy complications [12, 72, 73] . Clinical trials are eagerly awaited [17] . The European randomized controlled multicenter trial 'HYPATIA' will assess the role of HCQ versus placebo in pregnant women with aPL and hopefully provide more robust evidence on the use of HCQ in this setting [17] .
Complement activation, and therefore a potential role for eculizumab, has also been introduced as a potential target for APS therapy. The involvement of complement activation was first investigated in murine models of aPL-related pregnancy morbidities and growing evidences from both in-vitro and in-vivo studies are emerging [37, 38] . Complement can be activated by the binding of C3 fragment to the Fc receptor of aPL antibodies or by the formation of autoantibodies against C1q, which are frequently detected in patients with APS [74] . The activation of complement pathway and consequently production of inflammatory molecules like C5a by aPL can directly activate platelets and monocytes, inducing the coagulation cascade, leading to the clinical manifestations of APS.
Although in the current literature several case reports describe the successful use of eculizumab in severe cases of APS, such as CAPS and cases of APS and thrombotic microangiopathy, the potential role of eculizumab should be further investigated [3] .
CONCLUSION
APS is the most frequent acquired risk factor for a treatable cause of recurrent first trimester pregnancy loss and increases the risk of conditions associated with ischaemic placental dysfunction, including stillbirth, IUD, preeclamspia, premature birth and FGR. The current standard of care for obstetric APS is based on aspirin and LMWH. In refractory APS, steroids may play a role to improve pregnancy outcomes. New approaches aiming to improve pregnancy outcomes include the immune-modulator HCQ. Atorvastatin may have some beneficial effect in women with established aPL-related preeclampsia. Randomized controlled trials assessing these new treatment options are eagerly awaited.
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